

Patient and Surgeon Preferences Regarding the Port Delivery System and Intravitreal Injections for nAMD

July 6, 2020

Anaya J, Cheng E, Valentine K, Sepucha K, Ho A,
Regillo C



Financial Disclosure

- Regillo: Genentech sponsored study on the Port Delivery System
- Regillo and Ho: Genentech research grant funding and consulting


Summary

1. We hypothesize that both groups will prefer the implant with higher injection frequency
2. We hypothesize that both groups will be most concerned about factors that disfavor the implant

High Care Burden of Current nAMD Tx

ATLAS TAE Study of Aflibercept


Mean Treatment Interval at 2 years: 9 Weeks





High Care Burden of Current nAMD Tx

TREX Ranibizumab Extension Interval at 2 Years

Mean Max Extension: 8.5 Weeks




Port Delivery System for nAMD



2.5 mm diameter x 8 mm long
3.2 mm surgical incision
No vitrectomy


Decreased Injection Burden with Implantable Drug Delivery Device

80% high dose patients ≥ 6 months without refill




Decreased Injection Burden with Implantable Drug Delivery Device

Median time to 1st refill: 15 months



Preference-Based Decision



Purpose

- Understand patient and physician decision-making drivers for emerging nAMD treatment choices
- Develop patient decision support resources

Methods

- Developed physician- and patient- facing decision support materials
- Physician Survey
- Patient Survey

Hypothetical Treatment Choice

You are currently being treated with medication injections into your eye. A new treatment has been developed, and you are now faced with a hypothetical choice between two options: continued office-based injections or a device implant.

In this hypothetical choice, please consider the following:

- Both treatment options have similar benefits for your vision.
- Both treatment options will cost you about the same amount of money over two years.
- The device implant requires an operation.
- After the first month of the implant operation, the implant option involves fewer office visits and fewer in-office procedures.
- The risk of a serious eye infection is higher with the implant.
- There are other small risks with the implant. These include bleeding inside the eye, irritation or inflammation, and the possibility that the implant will need to be removed.

More details about what the treatments involve and how the risks compare are provided in the next pages.

Hypothetical Treatment Choice

You are currently being treated with medication injections into your eye. A new treatment has been developed, and you are now faced with a hypothetical choice between two options: *continued office-based injections or a device implant*

What do the hypothetical treatments involve?

In this hypothetical cho

- Both treatment op
- Both treatment op two years.
- The device implai
- After the first mo fewer office visits
- The risk of a serie
- There are other sn eye, irritation or i be removed.

More details about wha provided in the next pa

Continued Injections	Device Implant
<p>A medication is delivered into your eye with injections. Your office visits and injections will continue at about the same frequency. The frequency of your office visits and injections may increase or decrease depending on your disease activity and response to continued treatment.</p> <p>After 1 year of treatment, patients with your condition need in-office injections about once every 2 months, on average. The most frequently that you will need an eye injection is once every month. The least frequently that you will need an eye injection is once every 3 months.</p>	<p>A medication is delivered into your eye with a device implant. The device is implanted in the operating room. After the device implant operation, you will need 3 office visits within one month. You will then have an office visit about once every 3 months.</p> <p>After the device implant operation, patients with your condition need an in-office refill procedure about once every 6 months, on average. The most frequently that you will need an in-office refill procedure is once every 3 months. The least frequently that you will need an in-office refill procedure is once every 24 months. The ultimate frequency of the in-office refill procedure depends on disease activity and response to treatment.</p>

Hypothetical Treatment Choice

You are currently being treated with medication injections into your eye. A new treatment has been developed, and you are now faced with a hypothetical choice between two options: *continued office-based injections or a device implant*

What do the hypothetical treatments involve?

In this hypothetical cho

- Both treatment op
- Both treatment op two years.
- The device impla
- After the first mo fewer office visits
- The risk of a serie
- There are other sn eye, irritation or i be removed.

More details about wha provided in the next pa

Continued Injections	Device Implant
A medication is delivered into your eye with injections. Your office visits and injections will continue at about the same frequency. The frequency of your office visits and injections may increase or decrease depending on your disease activity and continued treatment.	A medication is delivered into your eye with a device implant. The device is implanted in the operating room. After the device implant operation, you will need 3 office visits within one month. You will then have an office visit about

How do the hypothetical treatment risks compare?

Continued Injections	Device Implant
About 2 in 10,000 patients experience a serious eye infection with a single injection. Depending on the number of injections given, up to about 50 in 10,000 patients may experience a serious eye infection.	About 200 in 10,000 patients experience a serious eye infection.
After 1 year of treatr your condition need about once every 2 n The most frequently an eye injection is or The least frequently an eye injection is or months.	Less than 500 in 10,000 patients with the implant experience bleeding inside the eye. This may cause temporary decreased vision that usually improves without treatment over 3 months. Less than 100 in 10,000 patients receiving the implant will need another surgery to remove the blood.
	About 500 in 10,000 patients will experience irritation or inflammation to the area of the eye around the implant

Inclusion Criteria

Physicians

Wills/Mid Atlantic
Retina

Patients

nAMD dx
> 50 years
> 2 injections

Data

- Pending

Thank you

- Mentors and Collaborators
 - Carl Regillo
 - Allen Ho
 - Karen Sepucha
 - KD Valentine
 - Ellie Cheng
- Wills Retina Research Team
 - Brianna Kenney
 - Michele Formoso